DAFNA Capital Management’s Aquestive Therapeutics AQST Stock Holding History

DAFNA Capital Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.69M	Buy	645,915 +277,500	+75%	+$1.17M	0.51%	40
2026 Q1	$1.53M	Sell	368,415 -7,500	-2%	-$30.4K	0.35%	51
2025 Q4	$2.43M	Sell	375,915 -136,674	-27%	-$852K	0.56%	44
2025 Q3	$2.87M	Buy	512,589 +370,589	+261%	+$1.6M	0.71%	37
2025 Q2	$470K	Hold	142,000	–	–	0.13%	66
2025 Q1	$412K	Buy	142,000 +15,000	+12%	+$45.4K	0.12%	74
2024 Q4	$452K	Sell	127,000 -462,561	-78%	-$2.13M	0.11%	73
2024 Q3	$2.94M	Buy	589,561 +59,561	+11%	+$232K	0.69%	37
2024 Q2	$1.38M	Buy	530,000 +30,000	+6%	+$100K	0.33%	53
2024 Q1	$2.13M	Buy	+500,000	New	+$1.66M	0.48%	42

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

DAFNA Capital Management's AQST Position: Q2 2026 in Review

DAFNA Capital Management increased its Aquestive Therapeutics (AQST) stake by 75% in Q2 2026, buying an estimated $1.17M and bringing the position to 645,915 shares worth $2.69M. The position accounts for 0.51% of the portfolio, ranked #40.

DAFNA Capital Management first reported a position in AQST in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.94M in Q3 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

DAFNA Capital Management held 645,915 shares of Aquestive Therapeutics worth $2.69M as of Q2 2026.
DAFNA Capital Management bought 277,500 Aquestive Therapeutics shares in Q2 2026, an estimated $1.17M.
Aquestive Therapeutics made up 0.51% of DAFNA Capital Management's portfolio in Q2 2026, its #40 holding.
DAFNA Capital Management first reported a position in Aquestive Therapeutics in Q1 2024 and has held it in 10 quarters since.
DAFNA Capital Management's Aquestive Therapeutics position peaked at $2.94M in Q3 2024.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.